Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Fortress Biotech (Nasdaq: FBIO), a biopharmaceutical company focused on acquiring and advancing assets, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Lindsay A. Rosenwald will deliver a corporate overview presentation, which will be available for on-demand viewing by conference attendees starting September 5, 2025, at 7:00 a.m. ET.
The company will also participate in virtual one-on-one meetings during the conference, scheduled for September 8-11, 2025.
Fortress Biotech (Nasdaq: FBIO), una società biofarmaceutica specializzata nell'acquisizione e nello sviluppo di asset, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. L'amministratore delegato Lindsay A. Rosenwald terrà una presentazione aziendale, disponibile on-demand per i partecipanti alla conferenza a partire dal 5 settembre 2025 alle 7:00 ET.
La società prenderà inoltre parte a incontri virtuali one-to-one programmati per il 8-11 settembre 2025.
Fortress Biotech (Nasdaq: FBIO), una compañía biofarmacéutica centrada en la adquisición y desarrollo de activos, anunció su participación en la H.C. Wainwright 27th Annual Global Investment Conference. La directora ejecutiva Lindsay A. Rosenwald ofrecerá una presentación corporativa, que estará disponible bajo demanda para los asistentes a la conferencia a partir del 5 de septiembre de 2025 a las 7:00 ET.
La compañía también participará en reuniones virtuales individuales durante la conferencia, programadas del 8 al 11 de septiembre de 2025.
Fortress Biotech (Nasdaq: FBIO)는 자산 인수 및 개발에 주력하는 바이오제약사로, H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다. CEO 린지 A. 로젠월드(Lindsay A. Rosenwald)가 회사 개요 프레젠테이션을 진행하며, 이 발표는 2025년 9월 5일 오전 7:00(동부 시간)부터 컨퍼런스 참가자들이 온디맨드로 시청할 수 있습니다.
회사는 또한 2025년 9월 8일~11일에 예정된 가상 1:1 미팅에도 참여합니다.
Fortress Biotech (Nasdaq: FBIO), une société biopharmaceutique spécialisée dans l'acquisition et le développement d'actifs, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. La PDG Lindsay A. Rosenwald présentera un aperçu de l'entreprise, qui sera disponible en replay pour les participants à la conférence à partir du 5 septembre 2025 à 7h00 ET.
La société participera également à des réunions virtuelles individuelles prévues du 8 au 11 septembre 2025.
Fortress Biotech (Nasdaq: FBIO), ein biopharmazeutisches Unternehmen, das sich auf den Erwerb und die Weiterentwicklung von Vermögenswerten konzentriert, gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference bekannt. CEO Lindsay A. Rosenwald wird eine Unternehmenspräsentation halten, die den Konferenzteilnehmern ab dem 5. September 2025 um 7:00 Uhr ET on-demand zur Verfügung steht.
Das Unternehmen wird außerdem an virtuellen One-on-One-Gesprächen während der Konferenz teilnehmen, die für den 8.–11. September 2025 angesetzt sind.
- None.
- None.
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 5, 2025, at 7:00 a.m. ET. The Company will also attend virtual one-on-one meetings during the conference taking place September 8-11, 2025.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has eight marketed prescription pharmaceutical products and multiple programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital, Columbia University, Dana Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When is Fortress Biotech (FBIO) presenting at the H.C. Wainwright Conference?
Who will present for Fortress Biotech at the H.C. Wainwright Conference?
What is the date range for the H.C. Wainwright Conference that FBIO is attending?
What type of meetings will Fortress Biotech conduct during the conference?
